"Combination Therapy To Treat Erythropoietin-Resistant Anemia In Chronic Kidney Disease" in Patent Application Approval Process (USPTO 20240197831).

A patent application has been filed for a combination therapy to treat erythropoietin-resistant anemia in chronic kidney disease. The therapy involves administering a first composition containing an erythropoiesis-stimulating agent (ESA) and a second composition containing a thrombopoietin receptor agonist (TPO-RA). The combination of these two agents aims to stimulate the expansion of hematopoietic stem cells and reduce the need for high-dose ESAs and blood transfusions. The patent application provides specific dosage ranges for the ESA and TPO-RA, as well as the timing and method of administration. [Extracted from the article]